Skip to main content
Canna~Fangled Abstracts

Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry

By July 9, 2024July 10th, 2024No Comments

. 2024 Jul 2.

doi: 10.1097/YIC.0000000000000556.

Online ahead of print.
Ann Francis 1, Simon Erridge 1 2, Carl Holvey 2, Ross Coomber 2 3, Rahul Guru 2 4, Alia Darweish Medniuk 2 5, Mohammed Sajad 2, Robert Searle 2, Azfer Usmani 2, Sanjay Varma 2, James Rucker 2 4 5, Michael Platt 2, Wendy Holden 2, Mikael H Sodergren 1 2
Affiliations 

Abstract

The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal products (CBMPs) and the safety of CBMPs in patients with inflammatory arthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. The primary outcomes changes were in Brief Pain Inventory, McGill Pain Questionnaire, EuroQol 5-dimension 5-level (EQ-5D-5L), Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months of follow-up compared with baseline. Adverse events were analyzed in accordance with Common Terminology Criteria for Adverse Events, v.4.0. Statistical significance was defined as a P-value less than 0.050. Eighty-two patients met the inclusion criteria. Initiation of CBMP treatment was associated with improvements in Brief Pain Inventory, McGill Pain Questionnaire, EQ-5D-5L, Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months compared with baseline (P < 0.050). There were 102 (44.35%) mild adverse events, 97 (42.17%) moderate adverse events, and 31 (13.48%) severe adverse events recorded by 21 (25.61%) participants. This study suggests that CBMP treatment is associated with pain improvement and increased health-related quality of life for inflammatory arthritis patients. While causality cannot be inferred in this observational study, the results support the development of randomized control trials for inflammatory arthritis pain management with CBMPs.

PubMed Disclaimer

References

    1. Bapir L, Erridge S, Nicholas M, Pillai M, Dalavaye N, Holvey C, et al. (2023). Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study. Expert Rev Neurother 23:281–295.
    1. Barrett EM, Scott DGI, Wiles NJ, Symmons DPM (2000). The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community‐based study. Br J Rheumatol 39:1403–1409.
    1. Barrie N, Manolios N (2017). The endocannabinoid system in pain and inflammation: its relevance to rheumatic disease. Eur J Rheumatol 4:210–218.
    1. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, et al. (2008). Opioid complications and side effects. Pain Physician 11(2 Suppl):S105–S120.
    1. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 45:50–52.

Leave a Reply